Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis

Table 4 Summary of meta-analysis outcomes for Japanese type 2 diabetes patients with short (<10 years) and long (≥10 years) duration of diabetes

Outcome	Effect estimate	95 % Confidence limits		p value	Effect estimate	95 % Confidence limits		p value
		Lower	Upper			Lower	Upper
		Short (<10 years) duration of diabetes				Long (≥10 years) duration of diabetes
Change in HbA1c (%)	−1.28	−1.65	−0.91	<0.0001	−0.93	−1.18	−0.67	<0.0001
Change in weight (kg)	−0.56	−1.34	0.21	0.16	−0.09	−0.66	0.47	0.75
Change in FPG (mg/dL)	−12.7	−26.6	1.2	0.07	−12.6	−24.9	−0.4	0.0438
Change in PPG: meal test (mg/dL)	−152.6	−182.0	−123.2	<0.0001	−147.9	−176.8	−119.0	<0.0001

	Odds ratio	95 % Confidence limits		p value	Odds ratio	95 % Confidence limits		p value
		Lower	Upper			Lower	Upper
		Short (<10 years) duration of diabetes				Long (≥10 years) duration of diabetes
Symptomatic hypoglycemia	5.2	1.5	18.7	0.0107	2.1	0.8	5.2	0.11
Severe hypoglycemia	0.0	0.0	0.0	–	0.0	0.0	0.0	–
Endpoint HbA1c <7 %	32.1	4.2	246.6	0.0009	8.9	2.5	31.9	0.0008
Endpoint HbA1c <7 % and no weight gain	22.5	2.9	174.3	0.0028	6.3	1.7	23.3	0.0057
Endpoint HbA1c <7 % and no symptomatic hypoglycemia	19.8	2.6	153.5	0.0043	9.0	2.0	41.1	0.0046
Endpoint HbA1c <7 % and no weight gain and no symptomatic hypoglycemia	11.6	1.4	93.3	0.0213	7.5	1.6	34.7	0.0099